NCT00505063

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 2 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.

Conditions

• Childhood Cancer
• Multiple Diseases

Interventions

Type	Name	Description
BIOLOGICAL	Immunization Schedule patients <7 years.	* Time 0 months: Prevnar 13 #1, Hib #1 * Time 1 months: Pediarix #1 * Time 2 months: Prevnar 13 #2, Hib #2 * Time 3-4 months: Pediarix #2 * Time 4-6 months: Draw post vaccine titers * Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.
BIOLOGICAL	Immunization Schedule patients > or = to 7 years and <11 years of age	* Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1 * Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2 * Time 2-3 months: Prevnar 13 #2, Hib #2 * Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations.
BIOLOGICAL	Immunization Schedule patients > or = to 11 years of age	* Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1 * Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2 * Time 2-3 months: Hib #2, Prevnar 13#2, Menactra * Time 3-6 months: IPV, Draw post vaccine titers * Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)

Timeline

• Start date: 2007-07-10
• Primary completion: 2025-06-11
• Completion: 2025-06-11
• First posted: 2007-07-20
• Last updated: 2025-06-15

Locations

1 site across 1 country: United States